Former head of the FDA Dr. Scott Gottlieb warned that the highly contagious, new mutation of Kovid-19 found in the United Kingdom is “already in the US” as more than 40 countries travel and ban from Britain for 48 hours or more is.
“I don’t think a travel ban is going, at this point, to stop this mutated strain from coming to the United States,” Gottli said. “We have an epidemic that continues to build up during the next three or four weeks, we will reach a peak, and then we will start to see a drop in infection rates as we see that vaccination has rolled out . “
A new version of Kovid-19 is forcing parts of the United Kingdom back into lockdown. The government imposed the most stringent restrictions in London as well as other areas in southeastern England, and families are no longer able to gather during Christmas, as previously planned. In an interview in CNBC’s “The News with Shepard Smith” on Monday evening, Gottlieb reported that the new mutation is likely a result of selective pressure on the virus.
“As the virus continues to spread around the world, we’re going to start seeing more of these variants, and that’s why it’s important to get the population vaccinated and smell these infections,” Gottlieb said. “The more infections you have, the more likely these variants start to propagate.”
Scientists in the UK suggested that the Kovid variant transmitted the virus 50% more, however, there is currently no indication that it makes the disease worse. Both Eli Lilly and Regeneron, who make antibody drugs to treat Kovid, said their drugs should be effective against the variant. According to Reuters, Ugur Sahin, the biotech’s chief executive, said his company would investigate the mutations, but he “looked at the situation with great humility.” BioNTech is Pfizer’s partner on the Kovid vaccine. Gottlieb hosted Shep Smith to explain why he felt the vaccines would eventually need to be adapted.
“The question is whether this virus is going to replace surface proteins in a way that can reduce vaccines or prior immunity, and there is no indication that it is doing it right now, but over time it develops in those ways Where it might happen Gatlib said, “Pre-infection or reducing vaccines to some extent, so we will need to adopt our vaccines over time.”
Morden’s first shipment of the Kovid vaccine affected hospitals across America today. Modern’s vaccine is the second after Pfizer to be authorized by the FDA. Morden’s rollout is expected to double this week, with the company planning to ship six million doses this week compared to Pfizer’s 2.9 million doses last week. Pfizer vaccines require temperatures of minus 94 degrees Fahrenheit, or minus 70 degrees Celsius. Modern can store their vaccines at minus 4 degrees F for six months.
Gottlieb said that the current logistics for vaccine delivery is “good”, but that there may be some challenges as the population is getting vaccine methods.
“I think the challenge is going to be the last mile, trying to distribute these vaccines in the community,” Gottlieb said. “Right now, in the month of December, we are distributing these vaccines on a large scale to health workers through medical institutions, educational hospitals, community hospitals, they know how to distribute a vaccine, their health Care workers have to find out. “
Disclosure: Scott Gottlieb is a CNBC contributor and a member of the boards of Pfizer, genetic testing start-up temps and biotech company Illumina. Has a manufacturing agreement with Pfizer Gilead For Remedisvir. Also serves as co-chairman of Gottlieb Norwegian Cruise Line Holdings‘And Royal Caribbean“Healthy Cell Panel.”